Key Features

• The platform spans the full authorization lifecycle for medical services/procedures (Auth Requirements, PolicyLink, AI-Driven Clinical Bundling, PolicyMatch, Policy Intelligence, Policy Digitization & Management, Submission Support, Smart Attestation Answering, Automated Statusing, Post-Auth Monitoring, CPT Mismatch detection, Analytics & Audit Trail, AI-Driven Clinical Review, Intelligent Gold-Carding, and AI-Driven Audit) and a comparable feature set for specialty drugs/infusions.
• Its goal is "90% touchless authorizations" with "two-minute human reviews" for the cases that do still require review.
• Independently confirmed via CMS's own WISeR Model Provider and Supplier Operational Guide (which lists Humata Health, Inc. among named WISeR Model Participants), Humata Health was selected by CMS as the primary technology partner conducting prior authorization and pre-payment medical review for all Traditional Medicare providers in Oklahoma under the federal WISeR (Wasteful and Inappropriate Service Reduction) Model, which went live January 1, 2026.
• Vendor-cited performance figures reported consistently across the R1 acquisition press coverage (GlobeNewswire, Fierce Healthcare, HIT Consultant, HLTH) include a 96% first-pass approval rate, a 30% reduction in write-offs, an 83% reduction in rescheduled appointments, and a 45% reduction in manual staff touches, these are figures both companies (R1 and Humata) are jointly citing in official acquisition materials, giving them a bit more institutional weight than a single vendor's own unaudited marketing page, though they remain company-reported rather than independently audited statistics.

Compliance & Security

• HIPAA Compliance: Yes
• FDA Status: Not applicable. Humata Health is administrative/utilization-management software (prior authorization workflow automation), not a clinical diagnostic or treatment device; no FDA filing was found or would be expected for this product category. Note that under the CMS WISeR model, the vendor's own program materials and independent reporting (HIT Consultant) state the AI can only issue approvals ("yes" decisions), with any non-affirmative or complex case automatically escalated to a human clinician - a notable design constraint given this tool touches Medicare coverage decisions, though this specific human-in-the-loop design applies to the WISeR government program context and may or may not describe every commercial deployment.
• Security certifications: According to the vendor's Security and Compliance page, Humata Health holds HITRUST CSF v9.5.0 r2 certification and undergoes annual SOC 2 Type II audits, with the report available upon request; these are stated in reasonable technical detail (a specific HITRUST framework version) compared to many vendors in this directory that only display generic badges.

Integration & Workflow

• EHR integration: Yes
• Platform: Web-based platform for providers, pharmacies, and payers, plus a dedicated "WISeR Portal" (psi.humatahealth.com) for the CMS federal program and a newer standalone portal (announced June 2026) specifically for independent/smaller-practice customers.

Pricing & Access

• Not publicly listed; the vendor directs prospective customers to "Contact us" rather than publishing pricing, consistent with an enterprise/health-system sales model.
• No free trial is advertised.

Doxiverse Assessment: Strengths & Limitations

• Strengths: Humata Health has an unusually strong, independently verifiable government-vetted credential for this category - direct confirmation via CMS's own official WISeR program documentation that it is a named federal technology partner handling live Medicare prior authorization decisions in Oklahoma, plus separate confirmed participation in CMS's Electronic Prior Authorization Acceleration Initiative. Its acquisition by R1 RCM (announced Aug. 18, 2026) signals strong market validation from an established, publicly known RCM company, and may bring additional institutional resources and integration scale once the deal closes.
• Limitations/Risks: The company-reported outcome statistics (96% first-pass approval, etc.) are cited jointly in acquisition-related press materials by both Humata and its acquirer, R1, rather than independently audited by a third party such as KLAS Research; no KLAS or comparable independent-evaluator report specific to Humata Health was found. Pricing is entirely non-public with no published starting point.

Ideal User Profile

• Best for: Hospitals and health systems

Disclaimer - This profile was compiled from publicly available sources including the vendor's own website, regulatory filings, press coverage, and independent research. Vendor claims are labeled as such and have not been independently audited by Doxiverse. Product features, pricing, certifications, and regulatory status change frequently and may no longer be current; verify all details directly with the vendor before making a purchasing decision. The "Doxiverse Assessment" and "Ideal User Profile" sections reflect Doxiverse's independent editorial analysis based on available sources at the time of writing, not the vendor's endorsement, and the vendor may disagree with this characterization. This profile is provided for informational purposes only and does not constitute a recommendation, endorsement, or professional/legal/clinical advice. Report inaccuracies to contact@doxiverse.com